Swiss generics and biosimilars major Sandoz (SIX: SDZ) today presented its net sales update for the first quarter of 2025.

In a recent study conducted by Navaneethan and colleagues and published in the International Society of Nephrology, the ...

US-Ireland drugmaker Shorla Oncology has received approval from the US regulator for a new multi-dose vial of Tepylute ...

Pfizer reported first-quarter 2025 earnings on Tuesday that beat Wall Street expectations, boosted by ongoing cost-cutting ...

Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) today announced financial results for the first quarter of 2025, showing ...

Italian pharma major Recordati (RECI: MI) has set new three-year financial targets for the period 2025-2027, aiming for ...

The European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing ...

A precision oncology company specializing in blood- and tissue-based genomic profiling to inform cancer treatment decisions.

Granite Bio AG, a clinical-stage immunology company based in Basel, Switzerland, and San Francisco, California, emerged from ...

Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer ...

Swiss pharma giant Novartis (NOVN: VX) this morning posted first-quarter 2025 financials, showing that net sales were $13.2 ...